Structure of protein pair provides blueprint for future drugs

Researchers have visualized for the first time how the protein SOCS1 ‘switches off’ cell signalling to dampen immune responses and block cancer growth. The atomic-level structure of SOCS1 binding to its partner protein JAK could guide the development of drugs that alter disease-causing cell signalling pathways, and may have applications for treating some blood cancers, including leukaemias.